Annals ofHIV - Aids

Volume: 5 - Number: 37 - January 15, 2006

Outstanding

Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy.

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

Global overview of injecting drug use and HIV infection among injecting drug users.

The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy.

BASIC SCIENCE

New CCR5 variants associated with reduced HIV coreceptor function in southeast Asia.

Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations

Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy.

CLINICAL SCIENCE

A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome.

Editorial reviews

Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C .

Barriers to participating in an HIV vaccine trial: a systematic review.

EPIDEMIOLOGY & SOCIAL

Global overview of injecting drug use and HIV infection among injecting drug users.

Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal.

The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy.

Infection with concurrent multiple hepatitis C virus genotypes is associated with faster HIV disease progression.

News

International AIDS Conference: Compliance issues Studies show long-term adherence to antiretroviral equals long-term efficacy.

Research letters

Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.

Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G.

Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients.

First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.